Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsQualChoice Redemplo (Plozasiran) Coverage Update |…
    Ask Trek AI about this page
    ModifiedQualChoicePolicy CP.PHAR.721

    Plozasiran (Redemplo) — coverage criteria for familial chylomicronemia syndrome

    Customize your policy alerts

    Sign up for QualChoice Policy CP.PHAR.721 alerts

    Get alerted when Policy CP.PHAR.721 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity criteria, prior authorization, and coverage for ploza­siran (Redemplo) as adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS) for QualChoice lines of business.

    Policy Summary
    PayerQualChoice
    PolicyPlozasiran (Redemplo) — Clinical/Medical Policy (coverage criteria)
    Policy CodePolicy CP.PHAR.721
    Change TypeMaterial updates to diagnostic and prescriber criteriaadded concurrent-therapy restriction
    Effective DateNov 18, 2025
    Next Review Date
    Key ActionSubmit prior authorization with office notes and lab results documenting FCS diagnosis and triglyceride history.
    SourceLink
    POLICY UPDATE CHANGES

    Added option for prescription by gastroenterologist or pancreatologist.

    In continued therapy, specified that Redemplo is not prescribed concurrently with Tryngolza.

    Consolidated FCS diagnostic criteria and added requirement for history of triglycerides >1,000 mg/dL at least three times for clinically suggestive FCS.

    Added ICHRA line of business.

    25 mg q3mApproved dosing regimen (FCS)
    ≥ 880 mg/dLLab threshold for diagnosis

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥ 18
    Minimum age
    6 moInitial auth length
    Pre-filled syringeProduct form

    Coverage Criteria

    inv-01: Initial Therapy

    Covered when ALL of the following are met for Initial Approval (FCS):

    Operational note: Provider must submit documentation (office chart notes, genetic test results if available, and fasting triglyceride laboratory results dated within 90 days) to support the diagnosis and eligibility criteria.

    inv-02: Continuation Therapy

    Covered when ALL of the following are met for Continued Therapy (FCS):

    Operational note: Approval duration: per line of business (see plan-specific rules); provide recent fasting triglyceride labs to document response from baseline.

    Non-FDA approved indications that are not specifically addressed in this policy are not authorized unless the request is supported by sufficient documentation of efficacy and safety per the applicable off-label use policy for the member's line of business (see: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid).

    Coverage determinations under this clinical policy are intended as medical necessity guidance only and are subject to all terms, conditions, exclusions, and limitations of the member's coverage documents (for example, evidence of coverage, certificate of coverage, policy, or contract of insurance) as well as applicable state and federal requirements and Health Plan administrative policies and procedures.

    Uses or requests that are not listed under the authorized diagnoses/indications in section III, and where a recent label change does not apply, should be routed to the off‑label use policies for the appropriate line of business (see CP.CPA.09, HIM.PA.154, CP.PMN.53). Such requests may be considered not medically necessary if they do not meet the applicable off‑label policy criteria.

    Initial Therapy — FCS

    Continuation Therapy — FCS

    inv-21: Continuation Therapy - FCS

    Criteria for continued therapy in FCS

    Operational note: Approval duration varies by line of business; submit recent fasting triglyceride lab results to document response. Continuity of care requests should reference applicable state addendums.

    Coding and Lab Thresholds

    HCPCS Codes referencedHCPCS
    C9399Unclassified drugs or biologicals
    J3490Unclassified drugs
    inv-07: Fasting triglycerides laboratory threshold
    ThresholdFasting triglycerides ≥ 880 mg/dL or ≥ 10 mmol/L (laboratory specimen dated within 90 days)
    Timing requirementMost recent fasting triglyceride lab must be dated within 90 days of request
    Role in criteriaRequired as part (a) of diagnostic evidence for Initial Approval of FCS
    inv-08: Clinically suggestive triglyceride history
    DefinitionHistory of elevated triglycerides >1,000 mg/dL on at least three occasions
    ContextUsed as part (ii) for clinically suggestive FCS when genetic testing is not confirmatory

    Provider Actions and Prior Authorization

    Prior Authorization

    Prior authorization required; use HCPCS C9399 or J3490 for unclassified drug billing

    Prior authorization is required for Redemplo; submit clinical documentation with the authorization request. For billing of unclassified drug products, use HCPCS codes C9399 (Unclassified drugs or biologicals) or J3490 (Unclassified drugs) as referenced in the policy.

    • Submit office chart notes and relevant lab results with the prior authorization request.
    • Reference HCPCS C9399 or J3490 when billing unclassified drug items.
    Note

    Prior authorization governed by plan-level procedures and member coverage

    This clinical policy is a medical-necessity guide used to support coverage decisions; actual prior authorization requirements and execution follow Health Plan-level administrative policies and the member's coverage documents.

    • Follow plan-specific prior authorization procedures and member coverage documents for submission and adjudication.

    Step Therapy

    StepRequirement / Routing
    1If the requested use is not listed in section III of this policy and a recent label change (within the last 6 months) does not apply, route the request to the applicable off‑label use policy for the member's line of business: CP.CPA.09 (Commercial), HIM.PA.154 (ICHRA/health insurance marketplace), or CP.PMN.53 (Medicaid).

    Quantity Limits

    inv-23: Plozasiran (Redemplo) — 25 mg
    ProductPlozasiran (Redemplo)
    Strength per dose25 mg
    Dosing interval25 mg subcutaneously every 3 months (maximum 25 mg per 3 months)

    Site of Care

    Note

    Pre-filled syringe available; no home site restriction specified

    Product is supplied as a pre‑filled syringe (25 mg/0.5 mL); the policy does not impose a specific site‑of‑care restriction for home use in this section.

    Note

    Office providers must follow Health Plan terms; no additional site‑of‑care rules specified

    Providers are independent contractors and must comply with Health Plan terms when providing services; the policy does not specify additional office site‑of‑care restrictions in this section.

    Background

    Plozasiran (Redemplo) is an siRNA therapeutic that targets apolipoprotein C‑III (apoC‑III) and is indicated, as an adjunct to diet, to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).

    Definitions and Policy Scope

    inv-18: FCS (familial chylomicronemia syndrome)
    DefinitionFamilial chylomicronemia syndrome (FCS) is a genetic disorder caused by biallelic loss-of-function pathogenic variants in genes such as LPL, APOC2, APOA5, GPIHBP1, and/or LMF1
    Diagnostic approachesFCS may be diagnosed clinically based on characteristic features; genetic testing can confirm but a negative result does not exclude FCS
    Also known asAlso referred to as lipoprotein lipase deficiency (LPLD) and multiple historical synonyms listed in Appendix D
    inv-19: Policy scope vs. clinical judgment
    Policy intentThis clinical policy is not medical advice and is not intended to dictate how providers practice medicine
    Provider responsibilityProviders are expected to exercise professional medical judgment and are solely responsible for medical advice and treatment decisions
    Policy Summary
    PayerQualChoice
    PolicyPlozasiran (Redemplo) — Clinical/Medical Policy (coverage criteria)
    Policy CodePolicy CP.PHAR.721
    Change TypeMaterial updates to diagnostic and prescriber criteriaadded concurrent-therapy restriction
    Effective DateNov 18, 2025
    Next Review Date
    Key ActionSubmit prior authorization with office notes and lab results documenting FCS diagnosis and triglyceride history.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy — FCSContinuation Therapy — FCSCoding and Lab ThresholdsProvider Actions and Prior AuthorizationStep TherapyQuantity LimitsSite of CareBackgroundDefinitions and Policy Scope
    Associated clinical featuresRequires one additional: history of pancreatitis, family history of hypertriglyceridemia, or recurrent unexplained abdominal pain
    Step Therapy

    Route requests for uses not listed to off‑label use policies per line of business

    If the requested use is not listed under section III of this policy and any recent FDA label change does not apply, route the request to the applicable off‑label use policy for the member's line of business (e.g., CP.CPA.09, HIM.PA.154, CP.PMN.53).

    • Refer to off‑label use policy per line of business when use is not covered by this policy.
    • Use referenced off‑label policies: CP.CPA.09 (Commercial), HIM.PA.154 (ICHRA), CP.PMN.53 (Medicaid).
    Note

    Unlabeled provider action

    (Placeholder) No additional unlabeled provider action text provided in the source policy.

    Documentation Required

    Submit office notes and labs showing FCS diagnosis and criteria

    Providers must submit supporting documentation such as office chart notes and laboratory results demonstrating diagnosis of familial chylomicronemia syndrome (FCS) and that the member meets the listed approval criteria (e.g., fasting triglycerides ≥ 880 mg/dL within 90 days, genetic testing or documented triglyceride history).

    • Include fasting triglyceride lab dated within 90 days showing ≥ 880 mg/dL (or ≥ 10 mmol/L) when available.
    • Include genetic testing confirming loss‑of‑function mutation OR documentation of triglycerides >1,000 mg/dL on at least three occasions plus associated clinical features.
    Note

    Providers must follow policy terms and applicable Health Plan procedures when submitting claims

    Providers and those submitting claims are bound by the terms and conditions of this clinical policy and must follow applicable Health Plan administrative policies and member coverage documents when providing services or requesting authorization.

    • Providers are independent contractors and agree to be bound by the policy terms when providing services or submitting claims.
    • Follow applicable Health Plan administrative policies and procedures in addition to this clinical policy.
    Denial Risk

    Missing documentation may lead to denial

    Failure to provide required documentation (office notes, lab results, or other clinical information) demonstrating that the member meets all approval criteria may result in denial of the authorization request.

    • Ensure submission of all requested clinical records to avoid adverse coverage determinations.
    Denial Risk

    Coverage decisions subject to member coverage documents and Health Plan rules (denial risk)

    Coverage and authorization decisions are subject to all terms, conditions, exclusions, and limitations of the member's coverage documents and applicable Health Plan policies and procedures; this policy does not guarantee payment.

    • Verify member benefits, exclusions, and plan‑level rules; state and federal requirements may also apply.
    Member guidanceMembers should consult with their treating physician for diagnosis and treatment decisions